MX2021006548A - Proteina de neurofilamento para guiar la intervencion terapeutica en la esclerosis lateral amiotrofica. - Google Patents
Proteina de neurofilamento para guiar la intervencion terapeutica en la esclerosis lateral amiotrofica.Info
- Publication number
- MX2021006548A MX2021006548A MX2021006548A MX2021006548A MX2021006548A MX 2021006548 A MX2021006548 A MX 2021006548A MX 2021006548 A MX2021006548 A MX 2021006548A MX 2021006548 A MX2021006548 A MX 2021006548A MX 2021006548 A MX2021006548 A MX 2021006548A
- Authority
- MX
- Mexico
- Prior art keywords
- lateral sclerosis
- amyotrophic lateral
- patient
- neurofilament protein
- therapeutic intervention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
Abstract
En un aspecto, la invención proporciona un método para aliviar un síntoma en un paciente con esclerosis lateral amiotrófica, que comprende la administración de un producto terapéutico eficaz que es eficaz para el paciente, el producto terapéutico eficaz, cuando se le administra al paciente, tiene como resultado un nivel de proteína de neurofilamento en una muestra biológica del paciente que es inferior que un nivel de proteína de neurofilamento en un paciente con esclerosis lateral amiotrófica al que no se le administró el producto terapéutico. En algunas modalidades, al paciente se le está administrando actualmente o se le ha administrado anteriormente un producto terapéutico no eficaz o un producto terapéutico que es diferente al producto terapéutico eficaz.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862776253P | 2018-12-06 | 2018-12-06 | |
US201962840431P | 2019-04-30 | 2019-04-30 | |
US201962842063P | 2019-05-02 | 2019-05-02 | |
PCT/US2019/064190 WO2020117772A1 (en) | 2018-12-06 | 2019-12-03 | Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021006548A true MX2021006548A (es) | 2021-09-21 |
Family
ID=68966114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021006548A MX2021006548A (es) | 2018-12-06 | 2019-12-03 | Proteina de neurofilamento para guiar la intervencion terapeutica en la esclerosis lateral amiotrofica. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220034907A1 (es) |
EP (1) | EP3890752A1 (es) |
JP (2) | JP2022513721A (es) |
KR (1) | KR20210102294A (es) |
CN (1) | CN113365640A (es) |
BR (1) | BR112021010660A2 (es) |
CA (1) | CA3121749A1 (es) |
MA (1) | MA54383A (es) |
MX (1) | MX2021006548A (es) |
WO (1) | WO2020117772A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200112906A (ko) | 2018-01-25 | 2020-10-05 | 바이오젠 엠에이 인코포레이티드 | 척추 근위축증의 치료 방법 |
JP2022536418A (ja) | 2019-06-11 | 2022-08-16 | キューリック・アンド・ソファ・ネザーランズ・ベーフェー | ディスクリート部品の組み立てにおける位置誤差の補償のための材料 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050019915A1 (en) * | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
WO2003000707A2 (en) | 2001-06-21 | 2003-01-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
KR102095429B1 (ko) | 2012-05-09 | 2020-03-31 | 바이오젠 엠에이 인코포레이티드 | 핵 수송 조절인자 및 이의 용도 |
US9963699B2 (en) | 2012-10-15 | 2018-05-08 | Ionis Pharmaceuticals, Inc. | Methods for modulating C9ORF72 expression |
JP6570447B2 (ja) | 2012-10-15 | 2019-09-04 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | C9orf72発現を調節するための組成物 |
US10577604B2 (en) | 2012-10-15 | 2020-03-03 | Ionis Pharmaceuticals, Inc. | Methods for monitoring C9ORF72 expression |
CA2889499C (en) * | 2012-10-24 | 2019-09-10 | Daiichi Sankyo Company, Limited | Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis |
SG11201602597YA (en) | 2013-10-11 | 2016-05-30 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
EP3058069B1 (en) | 2013-10-14 | 2019-07-24 | Ionis Pharmaceuticals, Inc. | Methods for modulating expression of c9orf72 antisense transcript |
US20160230172A1 (en) | 2013-10-14 | 2016-08-11 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
WO2015143245A1 (en) | 2014-03-19 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Methods for modulating ataxin 2 expression |
RS62526B1 (sr) | 2014-03-19 | 2021-11-30 | Ionis Pharmaceuticals Inc | Kompozicije za modulaciju ekspresije ataksina 2 |
EP4137573A3 (en) | 2014-04-01 | 2023-05-03 | Biogen MA Inc. | Compositions for modulating sod-1 expression |
NZ729808A (en) | 2014-09-30 | 2022-02-25 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
KR102599909B1 (ko) | 2014-11-14 | 2023-11-09 | 보이저 테라퓨틱스, 인크. | 근위축성 측삭 경화증(als)을 치료하는 조성물 및 방법 |
US10793855B2 (en) | 2015-01-06 | 2020-10-06 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
KR102104163B1 (ko) | 2015-04-16 | 2020-04-23 | 아이오니스 파마수티컬즈, 인코포레이티드 | C9orf72 발현을 조절하기 위한 조성물 |
WO2016167780A1 (en) | 2015-04-16 | 2016-10-20 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
AU2016381174A1 (en) | 2015-12-31 | 2018-05-31 | Ionis Pharmaceuticals, Inc. | Methods for reducing Ataxin-2 expression |
EP3443094B1 (en) | 2016-04-13 | 2022-10-19 | Ionis Pharmaceuticals, Inc. | Methods for reducing c9orf72 expression |
KR20200035301A (ko) | 2017-08-08 | 2020-04-02 | 웨이브 라이프 사이언시스 리미티드 | 올리고뉴클레오티드 조성물 및 이의 방법 |
KR20210018807A (ko) | 2018-04-27 | 2021-02-18 | 바이오젠 엠에이 인코포레이티드 | 인간-유래 항-(폴리-ga) 디펩타이드 반복 (dpr) 항체 |
-
2019
- 2019-12-03 BR BR112021010660-0A patent/BR112021010660A2/pt unknown
- 2019-12-03 JP JP2021531983A patent/JP2022513721A/ja not_active Withdrawn
- 2019-12-03 CA CA3121749A patent/CA3121749A1/en active Pending
- 2019-12-03 US US17/299,660 patent/US20220034907A1/en active Pending
- 2019-12-03 WO PCT/US2019/064190 patent/WO2020117772A1/en unknown
- 2019-12-03 MA MA054383A patent/MA54383A/fr unknown
- 2019-12-03 MX MX2021006548A patent/MX2021006548A/es unknown
- 2019-12-03 KR KR1020217020744A patent/KR20210102294A/ko unknown
- 2019-12-03 EP EP19824179.6A patent/EP3890752A1/en active Pending
- 2019-12-03 CN CN201980080522.8A patent/CN113365640A/zh active Pending
-
2024
- 2024-04-26 JP JP2024072811A patent/JP2024096258A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020117772A1 (en) | 2020-06-11 |
CN113365640A (zh) | 2021-09-07 |
CA3121749A1 (en) | 2020-06-11 |
EP3890752A1 (en) | 2021-10-13 |
JP2024096258A (ja) | 2024-07-12 |
MA54383A (fr) | 2021-10-13 |
BR112021010660A2 (pt) | 2021-08-24 |
JP2022513721A (ja) | 2022-02-09 |
KR20210102294A (ko) | 2021-08-19 |
US20220034907A1 (en) | 2022-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4303321A3 (en) | Antisense oligomers for treatment of conditions and diseases | |
MA47313B1 (fr) | Formulations sous-cutanées d'anticorps her2 | |
WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
MX2021000898A (es) | Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
MX2022013172A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
MX2016011975A (es) | Metodos para reducir el riesgo cardiovascular. | |
MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
WO2015123423A3 (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy | |
MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
MX2021006548A (es) | Proteina de neurofilamento para guiar la intervencion terapeutica en la esclerosis lateral amiotrofica. | |
MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
EP4252742A3 (en) | Fluticasone furoate in the treatment of copd | |
BR112017022653A2 (pt) | ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph? | |
SG10201906172XA (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
BR112017027277A2 (pt) | ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula? | |
PH12018502027A1 (en) | Methods of vitamin d treatment | |
AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
WO2020061355A3 (en) | Serum neurofilament protein for guiding therapeutic intervention in multiple sclerosis | |
MX2021007076A (es) | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. | |
BR112019002355A2 (pt) | composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme | |
MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
PH12020550066A1 (en) | METHOD FOR TREATING TNFa-RELATED DISEASE | |
WO2018089204A3 (en) | Combination therapies for treating bipolar disorder, and methods for using the same | |
CN105521549A (zh) | 一种治疗脚气的施药装置 |